Статті в журналах з теми "Anticancer drug treatment"
Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Anticancer drug treatment.
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Anticancer drug treatment".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
1
Alven, Sibusiso, and Blessing Atim Aderibigbe. "The Therapeutic Efficacy of Dendrimer and Micelle Formulations for Breast Cancer Treatment." Pharmaceutics 12, no. 12 (December 15, 2020): 1212. http://dx.doi.org/10.3390/pharmaceutics12121212.
Повний текст джерелаАнотація:
Breast cancer is among the most common types of cancer in women and it is the cause of a high rate of mortality globally. The use of anticancer drugs is the standard treatment approach used for this type of cancer. However, most of these drugs are limited by multi-drug resistance, drug toxicity, poor drug bioavailability, low water solubility, poor pharmacokinetics, etc. To overcome multi-drug resistance, combinations of two or more anticancer drugs are used. However, the combination of two or more anticancer drugs produce toxic side effects. Micelles and dendrimers are promising drug delivery systems that can overcome the limitations associated with the currently used anticancer drugs. They have the capability to overcome drug resistance, reduce drug toxicity, improve the drug solubility and bioavailability. Different classes of anticancer drugs have been loaded into micelles and dendrimers, resulting in targeted drug delivery, sustained drug release mechanism, increased cellular uptake, reduced toxic side effects of the loaded drugs with enhanced anticancer activity in vitro and in vivo. This review article reports the biological outcomes of dendrimers and micelles loaded with different known anticancer agents on breast cancer in vitro and in vivo.
2
Savinkova, A. V., E. M. Zhidkova, L. R. Tilova, M. D. Lavrova, E. S. Lylova, K. A. Kuzin, A. Yu Portyannikova, et al. "VARIANTS AND PERSPECTIVES OF DRUG REPURPOSING FOR CANCER TREATMENT." Siberian journal of oncology 17, no. 3 (July 4, 2018): 77–87. http://dx.doi.org/10.21294/1814-4861-2018-17-3-77-87.
Повний текст джерелаАнотація:
Recently many new approaches for repurposing or repositioning of the clinically used drugs have been developed. Drug repurposing allows not only to use known schemes for the synthesis of biologically active compounds, but also to avoid multiple studies that are necessary for drug approval process – analysis of pharmacokinetics, carcinogenicity, acute and chronic toxicity, including cardiotoxicity, nephrotoxicity, allergenicity etc. It makes possible to reduce the number of experimental studies as well as costs of investigations. In cancer research drug repurposing includes screening for medicines used nowadays for the treatment of patients with non-cancer diseases which possess anticancer activity or able to enhance the effects of the standard anticancer chemotherapy, and search for new applications of known anticancer drugs for the treatment of different cancer types. Scientific rationale for the search of the compounds with potential anticancer properties among drugs with different applications is based on the multiple cross-talks of signaling pathways, which can inhibit cell proliferation. Modern advances in genomics, proteomics and bioinformatics, development of permanently improving databases of drug molecular effects and high throughput analytical systems allow researchers to analyze simultaneously a large bulk of existing drugs and specific molecular targets. This review describes the main approaches and resources currently used for the drug repurposing, as well as a number of examples.
3
Mahmud, Kazi Mustafa, Mahruba Sultana Niloy, Md Salman Shakil, and Md Asiful Islam. "Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment." Pharmaceutics 13, no. 8 (August 19, 2021): 1295. http://dx.doi.org/10.3390/pharmaceutics13081295.
Повний текст джерелаАнотація:
Colorectal cancer (CRC) is one of the intimidating causes of death around the world. CRC originated from mutations of tumor suppressor genes, proto-oncogenes and DNA repair genes. Though platinum (Pt)-based anticancer drugs have been widely used in the treatment of cancer, their toxicity and CRC cells’ resistance to Pt drugs has piqued interest in the search for alternative metal-based drugs. Ruthenium (Ru)-based compounds displayed promising anticancer activity due to their unique chemical properties. Ru-complexes are reported to exert their anticancer activities in CRC cells by regulating different cell signaling pathways that are either directly or indirectly associated with cell growth, division, proliferation, and migration. Additionally, some Ru-based drug candidates showed higher potency compared to commercially available Pt-based anticancer drugs in CRC cell line models. Meanwhile Ru nanoparticles coupled with photosensitizers or anticancer agents have also shown theranostic potential towards CRC. Ru-nanoformulations improve drug efficacy, targeted drug delivery, immune activation, and biocompatibility, and therefore may be capable of overcoming some of the existing chemotherapeutic limitations. Among the potential Ru-based compounds, only Ru (III)-based drug NKP-1339 has undergone phase-Ib clinical trials in CRC treatment.
4
Lee, Jun H., and Anjan Nan. "Combination Drug Delivery Approaches in Metastatic Breast Cancer." Journal of Drug Delivery 2012 (April 26, 2012): 1–17. http://dx.doi.org/10.1155/2012/915375.
Повний текст джерелаАнотація:
Disseminated metastatic breast cancer needs aggressive treatment due to its reduced response to anticancer treatment and hence low survival and quality of life. Although in theory a combination drug therapy has advantages over single-agent therapy, no appreciable survival enhancement is generally reported whereas increased toxicity is frequently seen in combination treatment especially in chemotherapy. Currently used combination treatments in metastatic breast cancer will be discussed with their challenges leading to the introduction of novel combination anticancer drug delivery systems that aim to overcome these challenges. Widely studied drug delivery systems such as liposomes, dendrimers, polymeric nanoparticles, and water-soluble polymers can concurrently carry multiple anticancer drugs in one platform. These carriers can provide improved target specificity achieved by passive and/or active targeting mechanisms.
5
P. George, Christy, Shridhar H. Thorat, Parth S. Shaligram, Suresha P. R., and Rajesh G. Gonnade. "Drug–drug cocrystals of anticancer drugs erlotinib–furosemide and gefitinib–mefenamic acid for alternative multi-drug treatment." CrystEngComm 22, no. 37 (2020): 6137–51. http://dx.doi.org/10.1039/d0ce00353k.
Повний текст джерелаАнотація:
Drug–drug cocrystals of anticancer drugs erlotinib and gefitinib with furosemide and mefenamic acid, respectively, have been synthesized, characterized and their solubilities and dissolution rates were correlated with crystal structures.
6
Moradi-Marjaneh, Reyhaneh, Majid Khazaei, Sima Seifi, Seyed Mahdi Hassanian, Gordon A. Ferns, and Amir Avan. "Pharmacogenetics of Anticancer Drug Sensitivity and Toxicity in Colorectal Cancer." Current Pharmaceutical Design 24, no. 23 (October 24, 2018): 2710–18. http://dx.doi.org/10.2174/1381612824666180727144535.
Повний текст джерелаАнотація:
Inter-individual differences in drug response are an important cause of failure in anticancer treatment and adverse drug events in cancer patients. Gene polymorphisms related to these outcomes have been investigated in an effort to find new genetic biomarkers to predict toxicity and response to anticancer drugs. Evaluating the value single nucleotide polymorphisms (SNPs) in the genes involved in transportation, activation and metabolism of anticancer drugs provides a promising approach to select the appropriate therapeutic regimes with at least adverse reactions. This review summarizes the current knowledge about the relationship between of SNPs involved in the transportation, activation and metabolism of anticancer drugs and treatment outcomes in colorectal cancer (CRC) patients.
7
Ostroumova, O. D., D. A. Sychev, A. I. Kochetkov, T. M. Ostroumova, M. I. Kulikova, and V. A. De. "Anti-cancer agents and drug-induced hypertension." Medical alphabet, no. 17 (September 7, 2022): 30–41. http://dx.doi.org/10.33667/2078-5631-2022-17-30-41.
Повний текст джерелаАнотація:
Arterial hypertension is one of the most common comorbidities in patients with cancer. Moreover, the treatment with anticancer agents can lead to the development of drug-induced arterial hypertension. The aim of this work is to systematize and analyze data about anticancer agents, the use of which can cause the development of drug-induced hypertension, about epidemiology, pathophysiological mechanisms, risk factors, clinical signs, diagnosis and differential diagnosis, treatment and prevention of hypertension associated with the use of anticancer drugs. It was found that anti-cancer drugs often contribute to the development of drug-induced hypertension. The mechanisms that determine the development of hypertension are diverse and may include the development of endothelial dysfunction, an increased arterial stiffness, capillary rarefaction, fluid and electrolyte imbalance, and genetic factors. It is important to remember about drugs that can cause drug-induced hypertension to reduce the risk of developing adverse reactions, and prevent cardiovascular disease. Treatment of drug-induced hypertension, caused by anticancer drugs, often requires immediate discontinuation of drugs, due to adverse reactions that are often life-threatening. In some situations, it is possible to reduce the dose of the drugs and / or prescribe antihypertensive drugs. Arterial hypertension is an important risk factor in the development of cardiovascular events, including stroke, coronary heart disease, heart failure.
8
Li, Fan, Xinqing Fu, Qingqing Huo, and Wantao Chen. "Research Progress on the Nano-Delivery Systems of Antitumor Drugs." Nano LIFE 10, no. 01n02 (March 2020): 2040006. http://dx.doi.org/10.1142/s1793984420400061.
Повний текст джерелаАнотація:
To date, chemotherapy, the main treatment for malignant tumors, still fails to provide ideal therapeutic efficacy, which is deeply rooted in various physiological barriers, either temporal or spatial, to the delivering of anticancer drugs to solid tumor sites during chemotherapy. In the meantime, the therapeutic efficacy of anticancer drugs is affected by inherent cancer characteristics, drug transport, cellular uptake and other complex interactions. Recently, advances have been constantly achieved on nanoscale drug delivery systems (NDDSs) for anticancer drug delivery, driven by their excellent stability and effectiveness in improving water solubility of anticancer drugs, prolonging systemic circulation time, reducing side effects and improving anticancer effects. This paper presents an overview of the current research status and challenges in applying NDDSs to anticancer drug delivery.
9
Fumagalli, Gaia, Cristina Marucci, Michael S. Christodoulou, Barbara Stella, Franco Dosio, and Daniele Passarella. "Self-assembly drug conjugates for anticancer treatment." Drug Discovery Today 21, no. 8 (August 2016): 1321–29. http://dx.doi.org/10.1016/j.drudis.2016.06.018.
Повний текст джерела
10
Kim, Tae-Hyun, Gyeong Jin Lee, Joo-Hee Kang, Hyoung-Jun Kim, Tae-il Kim, and Jae-Min Oh. "Anticancer Drug-Incorporated Layered Double Hydroxide Nanohybrids and Their Enhanced Anticancer Therapeutic Efficacy in Combination Cancer Treatment." BioMed Research International 2014 (2014): 1–11. http://dx.doi.org/10.1155/2014/193401.
Повний текст джерелаАнотація:
Objective. Layered double hydroxide (LDH) nanoparticles have been studied as cellular delivery carriers for anionic anticancer agents. As MTX and 5-FU are clinically utilized anticancer drugs in combination therapy, we aimed to enhance the therapeutic performance with the help of LDH nanoparticles.Method. Anticancer drugs, MTX and 5-FU, and their combination, were incorporated into LDH by reconstruction method. Simply, LDHs were thermally pretreated at 400°C, and then reacted with drug solution to simultaneously form drug-incorporated LDH. Thus prepared MTX/LDH (ML), 5-FU/LDH (FL), and (MTX + 5-FU)/LDH (MFL) nanohybrids were characterized by X-ray diffractometer, scanning electron microscopy, infrared spectroscopy, thermal analysis, zeta potential measurement, dynamic light scattering, and so forth. The nanohybrids were administrated to the human cervical adenocarcinoma, HeLa cells, in concentration-dependent manner, comparing with drug itself to verify the enhanced therapeutic efficacy.Conclusion. All the nanohybrids successfully accommodated intended drug molecules in their house-of-card-like structures during reconstruction reaction. It was found that the anticancer efficacy of MFL nanohybrid was higher than other nanohybrids, free drugs, or their mixtures, which means the multidrug-incorporated LDH nanohybrids could be potential drug delivery carriers for efficient cancer treatment via combination therapy.
11
Singh, A., S. Bhatia, and V. Rana. "Inhalable Nanostructures for Lung Cancer Treatment: Progress and Challenges." Current Nanomedicine 9, no. 1 (March 15, 2019): 4–29. http://dx.doi.org/10.2174/2468187308666180307152049.
Повний текст джерелаАнотація:
Background: Worldwide, lung cancer is the major cause of deaths due to cancer. Most of the lung cancer cases are categorized as 85% cases of non-small cell lung cancer, while remainder 15% cases are known as small cell lung cancer. The long survival time as well as the improved quality of life for patients undergoing lung cancer using conventional chemotherapy is still not satisfactory. Therefore, robust research undergoes development of drug delivery system which increased drug at target side with reduced systemic side effect. Method: Bibliography database reviewed various inhalable nanostructured drug delivery strategies for effective delivery of anticancer drugs to lung cancer which are designed to improve the therapeutic index of anticancer drugs throughout improvement of their stability as well as bioavailability. Results: It has been reported that nanostructure based inhalation chemotherapy is more successful targeting system and also offers reduced side effects than conventional chemotherapy. Conclusion: Thus, the review highlights the critical issues, strategies for delivery and provides detail on various inhalable nanostructures for anticancer drug delivery along with toxicity concerns as well as rationale behind development of inhalable nanostructures.
12
Gurunathan, Sangiliyandi, Min-Hee Kang, Muhammad Qasim, and Jin-Hoi Kim. "Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer." International Journal of Molecular Sciences 19, no. 10 (October 20, 2018): 3264. http://dx.doi.org/10.3390/ijms19103264.
Повний текст джерелаАнотація:
Cancer represents a group of heterogeneous diseases characterized by uncontrolled growth and spread of abnormal cells, ultimately leading to death. Nanomedicine plays a significant role in the development of nanodrugs, nanodevices, drug delivery systems and nanocarriers. Some of the major issues in the treatment of cancer are multidrug resistance (MDR), narrow therapeutic window and undesired side effects of available anticancer drugs and the limitations of anticancer drugs. Several nanosystems being utilized for detection, diagnosis and treatment such as theranostic carriers, liposomes, carbon nanotubes, quantum dots, polymeric micelles, dendrimers and metallic nanoparticles. However, nonbiodegradable nanoparticles causes high tissue accumulation and leads to toxicity. MDR is considered a major impediment to cancer treatment due to metastatic tumors that develop resistance to chemotherapy. MDR contributes to the failure of chemotherapies in various cancers, including breast, ovarian, lung, gastrointestinal and hematological malignancies. Moreover, the therapeutic efficiency of anticancer drugs or nanoparticles (NPs) used alone is less than that of the combination of NPs and anticancer drugs. Combination therapy has long been adopted as the standard first-line treatment of several malignancies to improve the clinical outcome. Combination therapy with anticancer drugs has been shown to generally induce synergistic drug actions and deter the onset of drug resistance. Therefore, this review is designed to report and analyze the recent progress made to address combination therapy using NPs and anticancer drugs. We first provide a comprehensive overview of the angiogenesis and of the different types of NPs currently used in treatments of cancer; those emphasized in this review are liposomes, polymeric NPs, polymeric micelles (PMs), dendrimers, carbon NPs, nanodiamond (ND), fullerenes, carbon nanotubes (CNTs), graphene oxide (GO), GO nanocomposites and metallic NPs used for combination therapy with various anticancer agents. Nanotechnology has provided the convenient tools for combination therapy. However, for clinical translation, we need continued improvements in the field of nanotechnology.
13
Kumar, Maushmi S., Tanuja T. Yadav, Rohan R. Khair, Godefridus J. Peters, and Mayur C. Yergeri. "Combination Therapies of Artemisinin and its Derivatives as a Viable Approach for Future Cancer Treatment." Current Pharmaceutical Design 25, no. 31 (November 14, 2019): 3323–38. http://dx.doi.org/10.2174/1381612825666190902155957.
Повний текст джерелаАнотація:
Background: Many anticancer drugs have been developed for clinical usage till now, but the major problem is the development of drug-resistance over a period of time in the treatment of cancer. Anticancer drugs produce huge adverse effects, ultimately leading to death of the patient. Researchers have been focusing on the development of novel molecules with higher efficacy and lower toxicity; the anti-malarial drug artemisinin and its derivatives have exhibited cytotoxic effects. Methods: We have done extensive literature search for artemisinin for its new role as anti-cancer agent for future treatment. Last two decades papers were referred for deep understanding to strengthen its role. Results: Literature shows changes at 9, 10 position in the artemisinin structure produces anticancer activity. Artemisinin shows anticancer activity in leukemia, hepatocellular carcinoma, colorectal and breast cancer cell lines. Artemisinin and its derivatives have been studied as combination therapy with several synthetic compounds, RNA interfaces, recombinant proteins and antibodies etc., for synergizing the effect of these drugs. They produce an anticancer effect by causing cell cycle arrest, regulating signaling in apoptosis, angiogenesis and cytotoxicity activity on the steroid receptors. Many novel formulations of artemisinin are being developed in the form of carbon nanotubes, polymer-coated drug particles, etc., for delivering artemisinin, since it has poor water/ oil solubility and is chemically unstable. Conclusion: We have summarize the combination therapies of artemisinin and its derivatives with other anticancer drugs and also focussed on recent developments of different drug delivery systems in the last 10 years. Various reports and clinical trials of artemisinin type drugs indicated selective cytotoxicity along with minimal toxicity thus projecting them as promising anti-cancer agents in future cancer therapies.
14
Sultana, Tania, Umair Jan, and Jeong Ik Lee. "Double Repositioning: Veterinary Antiparasitic to Human Anticancer." International Journal of Molecular Sciences 23, no. 8 (April 13, 2022): 4315. http://dx.doi.org/10.3390/ijms23084315.
Повний текст джерелаАнотація:
Drug repositioning, the approach of discovering different uses for existing drugs, has gained enormous popularity in recent years in the anticancer drug discovery field due to the increasing demand for anticancer drugs. Additionally, the repurposing of veterinary antiparasitic drugs for the treatment of cancer is gaining traction, as supported by existing literature. A prominent example is the proposal to implement the use of veterinary antiparasitics such as benzimidazole carbamates and halogenated salicylanilides as novel anticancer drugs. These agents have revealed pronounced anti-tumor activities and gained special attention for “double repositioning”, as they are repurposed for different species and diseases simultaneously, acting via different mechanisms depending on their target. As anticancer agents, these compounds employ several mechanisms, including the inhibition of oncogenic signal transduction pathways of mitochondrial respiration and the inhibition of cellular stress responses. In this review, we summarize and provide valuable information about the experimental, preclinical, and clinical trials of veterinary antiparasitic drugs available for the treatment of various cancers in humans. This review suggests the possibility of new treatment options that could improve the quality of life and outcomes for cancer patients in comparison to the currently used treatments.
15
Ramachandiran, Balaji, Biswajit Dubashi, Smita Kayal, Vikas Menon, K. Yuvaraj, C. Deepika, Deepa Francis, Deeksha Debbarma, and Devika S. Nair. "Assessment of Oral Anticancer Medication Adherence: A Survey from a Tertiary Cancer Center." South Asian Journal of Cancer 10, no. 02 (April 2021): 127–30. http://dx.doi.org/10.1055/s-0041-1723120.
Повний текст джерелаАнотація:
Abstract Background Adherence to oral anticancer medication is important in cancer chemotherapy, with the advent of many oral anticancer regimens to ensure adequate cytologic response. Literature on adherence to oral anticancer therapy in India is very less. Materials and Methods This is a cross sectional analytical study consisting of all fit patients > 18 years of age taking oral anticancer therapy, with or without intravenous (IV) chemotherapy. Adherence was determined using Morisky–Green–Levine (MGL) scale, and factors affecting adherence details about cancer and treatment were obtained. All fit patients were recruited. Information was obtained using Tamil questionnaire and pro forma. Observation Of 152 patients, only 111 patients were found to be adherent to treatment. The mean age of the study population was 49.03 ± 13.48 years. Only 12.5% of patients were aware of the diagnosis, treatment, and outcome. The study population consisted mainly of patients with chronic myeloid leukemia, colorectal carcinoma, breast carcinoma, and stomach carcinoma, which amounted for 78.3% of the study population. Bivariate analysis concluded that duration of treatment, adverse drug reaction (ADR), duration of oral anticancer drug intake in a month, coadministration with IV anticancer drugs, and frequency of drug intake (anticancer drug) were significant factors affecting drug adherence. Multivariate analysis of the above variables was insignificant, but ADR tended toward significance. Conclusion Drug adherence plays a major role in treatment outcome in cancer patients. ADR was independently associated with decreased drug adherence. Key interventions which should include counseling and behavioral modifications will reduce nonadherence.
16
Kumar, Girish, Tarun Virmani, Ashwani Sharma, and Kamla Pathak. "Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers." Pharmaceutics 15, no. 3 (March 9, 2023): 889. http://dx.doi.org/10.3390/pharmaceutics15030889.
Повний текст джерелаАнотація:
Anticancer drugs in monotherapy are ineffective to treat various kinds of cancer due to the heterogeneous nature of cancer. Moreover, available anticancer drugs possessed various hurdles, such as drug resistance, insensitivity of cancer cells to drugs, adverse effects and patient inconveniences. Hence, plant-based phytochemicals could be a better substitute for conventional chemotherapy for treatment of cancer due to various properties: lesser adverse effects, action via multiple pathways, economical, etc. Various preclinical studies have demonstrated that a combination of phytochemicals with conventional anticancer drugs is more efficacious than phytochemicals individually to treat cancer because plant-derived compounds have lower anticancer efficacy than conventional anticancer drugs. Moreover, phytochemicals suffer from poor aqueous solubility and reduced bioavailability, which must be resolved for efficacious treatment of cancer. Therefore, nanotechnology-based novel carriers are employed for codelivery of phytochemicals and conventional anticancer drugs for better treatment of cancer. These novel carriers include nanoemulsion, nanosuspension, nanostructured lipid carriers, solid lipid nanoparticles, polymeric nanoparticles, polymeric micelles, dendrimers, metallic nanoparticles, carbon nanotubes that provide various benefits of improved solubility, reduced adverse effects, higher efficacy, reduced dose, improved dosing frequency, reduced drug resistance, improved bioavailability and higher patient compliance. This review summarizes various phytochemicals employed in treatment of cancer, combination therapy of phytochemicals with anticancer drugs and various nanotechnology-based carriers to deliver the combination therapy in treatment of cancer.
17
Rohit Deepak Nalawade and Bhagwan Dilip Devkar. "Olaparib an anticancer drug: A review." World Journal of Advanced Research and Reviews 11, no. 2 (August 30, 2021): 329–36. http://dx.doi.org/10.30574/wjarr.2021.11.2.0406.
Повний текст джерелаАнотація:
Olaparib is an anti-cancer drug which comes under N-acyl piperazines class. The action of olaparib is PRPA inhibition. Drug taken by oral route which shows action in 1 to 3 hrs. after administration. It is FDA approved drug for various cancer treatment such as ovarian cancer, breast cancer, prostatic cancer and pancreatic cancer. Olaparib also useful different mutation conditions such as BRCA1/2 mutation. Olaparib prescribes after the chemotherapy treatment either singly or in combination. In serious and advanced mutation conditions combination therapy used. In this review paper, we put a narrative information about olaparib action, treatment approaches, pharmacokinetics, dosing regimen and resistance. Here we briefly give information about resistance mechanism of olaparib, treatment approaches in ovarian cancer, breast cancer and prostate cancer.
18
Elekofehinti, Olusola Olalekan, Opeyemi Iwaloye, Femi Olawale, and Esther Opeyemi Ariyo. "Saponins in Cancer Treatment: Current Progress and Future Prospects." Pathophysiology 28, no. 2 (June 5, 2021): 250–72. http://dx.doi.org/10.3390/pathophysiology28020017.
Повний текст джерелаАнотація:
Saponins are steroidal or triterpenoid glycoside that is distinguished by the soap-forming nature. Different saponins have been characterized and purified and are gaining attention in cancer chemotherapy. Saponins possess high structural diversity, which is linked to the anticancer activities. Several studies have reported the role of saponins in cancer and the mechanism of actions, including cell-cycle arrest, antioxidant activity, cellular invasion inhibition, induction of apoptosis and autophagy. Despite the extensive research and significant anticancer effects of saponins, there are currently no known FDA-approved saponin-based anticancer drugs. This can be attributed to a number of limitations, including toxicities and drug-likeness properties. Recent studies have explored options such as combination therapy and drug delivery systems to ensure increased efficacy and decreased toxicity in saponin. This review discusses the current knowledge on different saponins, their anticancer activity and mechanisms of action, as well as promising research within the last two decades and recommendations for future studies.
19
Fulda, Simone. "Targeting autophagy for the treatment of cancer." Biological Chemistry 399, no. 7 (June 27, 2018): 673–77. http://dx.doi.org/10.1515/hsz-2018-0105.
Повний текст джерелаАнотація:
Abstract Macroautophagy (herein termed autophagy) is evolutionarily highly conserved across eukaryotic cells and represents an intracellular catabolic process that targets damaged macromolecules and organelles for degradation. Autophagy is dysregulated in various human diseases including cancer. In addition, many drugs currently used for the treatment of cancer can engage autophagy, which typically promotes cancer cell survival by mitigating cellular stress. However, under certain circumstances activation of autophagy upon anticancer drug treatment can also trigger a lethal type of autophagy termed autophagic cell death (ACD). This may pave new avenues for exploiting the autophagic circuitry in oncology. This review presents the concept and some examples of anticancer drug-induced ACD.
20
Visconti, Roberta, and Domenico Grieco. "Fighting tubulin-targeting anticancer drug toxicity and resistance." Endocrine-Related Cancer 24, no. 9 (September 2017): T107—T117. http://dx.doi.org/10.1530/erc-17-0120.
Повний текст джерелаАнотація:
Tubulin-targeting drugs, like taxanes and vinca alkaloids, are among the most effective anticancer therapeutics used in the clinic today. Specifically, anti-microtubule cancer drugs (AMCDs) have proven to be effective in the treatment of castration-resistant prostate cancer and triple-negative breast cancer. AMCDs, however, have limiting toxicities that include neutropenia and neurotoxicity, and, in addition, tumor cells can become resistant to the drugs after long-term use. Co-targeting mitotic progression/slippage with inhibition of the protein kinases WEE1 and MYT1 that regulate CDK1 kinase activity may improve AMCD efficacy, reducing the acquisition of resistance by the tumor and side effects from the drug and/or its vehicle. Other possible treatments that improve outcomes in the clinic for these two drug-resistant cancers, including new formulations of the AMCDs and pursuing different molecular targets, will be discussed.
21
Ng, Chau Yee, Chun-Bing Chen, Ming-Ying Wu, Jennifer Wu, Chih-Hsun Yang, Rosaline Chung-Yee Hui, Ya-Ching Chang, and Chun-Wei Lu. "Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies." Journal of Immunology Research 2018 (2018): 1–9. http://dx.doi.org/10.1155/2018/5376476.
Повний текст джерелаАнотація:
Cutaneous adverse drug reactions are commonly seen in patients with anticancer drug treatment. Anticancer drugs, including chemotherapy, target therapy, and recent immunotherapy causing skin reactions ranging from mild skin rash to life-threatening severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) with increase morbidity and mortality while they are receiving cancer treatments, have been proposed to be a result of direct skin toxicity or drug hypersensitivity reactions (these are proposed mechanism, not definite). Differentiating SCARs from other more commonly seen reactions with a better outcome help prevent discontinuation of therapy and inappropriate use of systemic immunosuppressants for presumable allergic reactions, of which will affect the clinical outcome. In this article, we have reviewed published articles from 1950 to August 2017 for SJS/TEN associated with anticancer drugs, including chemotherapy, targeted therapy, and immunotherapy. We aimed to provide an overview of SJS/TEN associated with anticancer drugs to increase clinician recognition and accelerate future studies on the pathomechanism and managements.
22
Majumder, Nairrita, Nandita G Das, and Sudip K. Das. "Polymeric micelles for anticancer drug delivery." Therapeutic Delivery 11, no. 10 (October 2020): 613–35. http://dx.doi.org/10.4155/tde-2020-0008.
Повний текст джерелаАнотація:
Polymeric micelles have gained interest as novel drug delivery systems for the treatment and diagnosis of cancer, as they offer several advantages over conventional drug therapies. This includes drug targeting to tumor tissue, in vivo biocompatibility and biodegradability, prolonged circulation time, enhanced accumulation, retention of the drug loaded micelle in the tumor and decreased side effects. This article provides an overview on the current state of micellar formulations as nanocarriers for anticancer drugs and their effectiveness in cancer therapeutics, including their clinical status. The type of copolymers used, their physicochemical properties and characterization as well as recent developments in the design of functional polymeric micelles are highlighted. The article also presents the design and outcomes of various types of stimuli-responsive polymeric micelles.
23
Ahtit, Mustapha, Soulaymani Abdelmajid, Khadmaoui Abderrazak, R. Benkirane, Soulaymani Bencheikh Rachida, and E. Kerak. "Les Effets Indésirables Digestifs De La Chimiothérapie : Cas Des Patients De L’institut National D’oncologie De Rabat (Maroc)." European Scientific Journal, ESJ 12, no. 33 (November 30, 2016): 454. http://dx.doi.org/10.19044/esj.2016.v12n33p454.
Повний текст джерелаАнотація:
An adverse reaction of an anticancer drug is a harmful and an unintended reaction by patient suffering from cancer disease who is often polymedicated. The treatment of cancers by anti-cancer molecules produces serious adverse drug effects. The main purpose of this paper is to present and evaluate the digestive adverse effects involved in anti-cancer drugs and their potential of correlation to anticipate, prevent and improve the quality of care of patient suffering from cancer disease. This is a prospective study that that enrolled 147 patients seen between January 25 and June 25, 2009 with adverse drug reactions due to an anticancer treatment. Breast and cavum cancers present 34% of cases. The average age was 46.52 years. The sex ratio (M / F) was 0.33. During the study period 283 Adverse drug effects of anticancer drugs were collected with a predominance (132) adverse digestive effects and 32 anticancer drugs were counted on all medical prescriptions. Nausea and vomiting are the most common side effects, sometimes very severe. The availability of anti-emetics in the family of 5-HT3 serotoninergic antagonists has considerably improved the experience of patients undergoing anticancer chemotherapy, hence the importance of pharmacovigilance as a tool is to improve the quality of anticancer care.
24
Ibrahim, Hassan M., Omar A. Farid, Amany Samir, and Rehab M. Mosaad. "Preparation of Chitosan Antioxidant Nanoparticles as Drug Delivery System for Enhancing of Anti-Cancer Drug." Key Engineering Materials 759 (January 2018): 92–97. http://dx.doi.org/10.4028/www.scientific.net/kem.759.92.
Повний текст джерелаАнотація:
Chemotherapy is a major therapeutic approach for the treatment of localized and metastasized cancers. Although Doxorubicin (DOX) possesses abroad spectrum of anticancer activity, its clinical use is limited because of it cause heart failure. Chitosan nanoparticles was prepared by using ionic gelation method. These nanoaparticles were used as polyload of anticancer DOX to form safer and non-toxic anticancer drug. infrared spectroscopy (FTIR) and transmission electron microscope (TEM) were used to characterize the prepared nanoparticles. The cancer animals’ experiments using Ehrlich static cancer, (EAC) cells using six groups of experimental animals were performed to evaluate the efficiency of Doxorubicin and Doxorubicin loaded chitosan nanoparticles as anticancer drug especially from its toxicity towards heart. Tumor volume was calculated as to monitor the response to treatment. Cytotoxicity of Doxorubicin and Doxorubicin loaded chitosan nanoparticles were evaluated. Biochemical parameters were be estimated to illustrate the cytotoxicity of these drugs on heart.
25
Wang, Ying, and Jen-Fu Chiu. "Proteomic Approaches in Understanding Action Mechanisms of Metal-Based Anticancer Drugs." Metal-Based Drugs 2008 (July 22, 2008): 1–9. http://dx.doi.org/10.1155/2008/716329.
Повний текст джерелаАнотація:
Medicinal inorganic chemistry has been stimulating largely by the success of the anticancer drug, cisplatin. Various metal complexes are currently used as therapeutic agents (e.g., Pt, Au, and Ru) in the treatment of malignant diseases, including several types of cancers. Understanding the mechanism of action of these metal-based drugs is for the design of more effective drugs. Proteomic approaches combined with other biochemical methods can provide comprehensive understanding of responses that are involved in metal-based anticancer drugs-induced cell death, including insights into cytotoxic effects of metal-based anticancer drugs, correlation of protein alterations to drug targets, and prediction of drug resistance and toxicity. This information, when coupled with clinical data, can provide rational basses for the future design and modification of present used metal-based anticancer drugs.
26
Alven, Sibusiso, Xhamla Nqoro, Buhle Buyana, and Blessing A. Aderibigbe. "Polymer-Drug Conjugate, a Potential Therapeutic to Combat Breast and Lung Cancer." Pharmaceutics 12, no. 5 (April 29, 2020): 406. http://dx.doi.org/10.3390/pharmaceutics12050406.
Повний текст джерелаАнотація:
Cancer is a chronic disease that is responsible for the high death rate, globally. The administration of anticancer drugs is one crucial approach that is employed for the treatment of cancer, although its therapeutic status is not presently satisfactory. The anticancer drugs are limited pharmacologically, resulting from the serious side effects, which could be life-threatening. Polymer drug conjugates, nano-based drug delivery systems can be utilized to protect normal body tissues from the adverse side effects of anticancer drugs and also to overcome drug resistance. They transport therapeutic agents to the target cell/tissue. This review article is based on the therapeutic outcomes of polymer-drug conjugates against breast and lung cancer.
27
Meegan, Mary J., and Niamh M. O’Boyle. "Special Issue “Anticancer Drugs”." Pharmaceuticals 12, no. 3 (September 16, 2019): 134. http://dx.doi.org/10.3390/ph12030134.
Повний текст джерелаАнотація:
The focus of this Special Issue of Pharmaceuticals is on the design, synthesis, and molecular mechanism of action of novel antitumor, drugs with a special emphasis on the relationship between the chemical structure and the biological activity of the molecules. This Special Issue also provides an understanding of the biologic and genotypic context in which targets are selected for oncology drug discovery, thus providing a rationalization for the biological activity of these drugs and guiding the design of more effective agents. In this Special Issue of Pharmaceuticals dedicated to anticancer drugs, we present a selection of preclinical research papers including both traditional chemotherapeutic agents and newer more targeted therapies and biological agents. We have included articles that report the design of small molecules with promising anticancer activity as tubulin inhibitors, vascular targeting agents, and topoisomerase targeting agents, alongside a comprehensive review of clinically successful antibody-drug conjugates used in cancer treatment.
28
Lee, Jae-Seon, Ho Lee, Hyonchol Jang, Sang Myung Woo, Jong Bae Park, Seon-Hyeong Lee, Joon Hee Kang, Hee Yeon Kim, Jaewhan Song, and Soo-Youl Kim. "Targeting Oxidative Phosphorylation Reverses Drug Resistance in Cancer Cells by Blocking Autophagy Recycling." Cells 9, no. 9 (September 1, 2020): 2013. http://dx.doi.org/10.3390/cells9092013.
Повний текст джерелаАнотація:
The greatest challenge in cancer therapy is posed by drug-resistant recurrence following treatment. Anticancer chemotherapy is largely focused on targeting the rapid proliferation and biosynthesis of cancer cells. This strategy has the potential to trigger autophagy, enabling cancer cell survival through the recycling of molecules and energy essential for biosynthesis, leading to drug resistance. Autophagy recycling contributes amino acids and ATP to restore mTOR complex 1 (mTORC1) activity, which leads to cell survival. However, autophagy with mTORC1 activation can be stalled by reducing the ATP level. We have previously shown that cytosolic NADH production supported by aldehyde dehydrogenase (ALDH) is critical for supplying ATP through oxidative phosphorylation (OxPhos) in cancer cell mitochondria. Inhibitors of the mitochondrial complex I of the OxPhos electron transfer chain and ALDH significantly reduce the ATP level selectively in cancer cells, terminating autophagy triggered by anticancer drug treatment. With the aim of overcoming drug resistance, we investigated combining the inhibition of mitochondrial complex I, using phenformin, and ALDH, using gossypol, with anticancer drug treatment. Here, we show that OxPhos targeting combined with anticancer drugs acts synergistically to enhance the anticancer effect in mouse xenograft models of various cancers, which suggests a potential therapeutic approach for drug-resistant cancer.
29
Franzese, Ornella, Francesco Torino, Elisa Giannetti, Giorgia Cioccoloni, Angelo Aquino, Isabella Faraoni, Maria Pia Fuggetta, et al. "Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?" International Journal of Molecular Sciences 22, no. 19 (October 1, 2021): 10672. http://dx.doi.org/10.3390/ijms221910672.
Повний текст джерелаАнотація:
The current state of cancer treatment is still far from being satisfactory considering the strong impairment of patients’ quality of life and the high lethality of malignant diseases. Therefore, it is critical for innovative approaches to be tested in the near future. In view of the crucial role that is played by tumor immunity, the present review provides essential information on the immune-mediated effects potentially generated by the interplay between ionizing radiation and cytotoxic antitumor agents when interacting with target malignant cells. Therefore, the radiation-dependent abscopal effect (i.e., a biological effect of ionizing radiation that occurs outside the irradiated field), the influence of cancer chemotherapy on the antigenic pattern of target neoplastic cells, and the immunogenic cell death (ICD) caused by anticancer agents are the main topics of this presentation. It is widely accepted that tumor immunity plays a fundamental role in generating an abscopal effect and that anticancer drugs can profoundly influence not only the host immune responses, but also the immunogenic pattern of malignant cells. Remarkably, several anticancer drugs impact both the abscopal effect and ICD. In addition, certain classes of anticancer agents are able to amplify already expressed tumor-associated antigens (TAA). More importantly, other drugs, especially triazenes, induce the appearance of new tumor neoantigens (TNA), a phenomenon that we termed drug-induced xenogenization (DIX). The adoption of the abscopal effect is proposed as a potential therapeutic modality when properly applied concomitantly with drug-induced increase in tumor cell immunogenicity and ICD. Although little to no preclinical or clinical studies are presently available on this subject, we discuss this issue in terms of potential mechanisms and therapeutic benefits. Upcoming investigations are aimed at evaluating how chemical anticancer drugs, radiation, and immunotherapies are interacting and cooperate in evoking the abscopal effect, tumor xenogenization and ICD, paving the way for new and possibly successful approaches in cancer therapy.
30
Tang, Lu, Jing Li, Qingqing Zhao, Ting Pan, Hui Zhong, and Wei Wang. "Advanced and Innovative Nano-Systems for Anticancer Targeted Drug Delivery." Pharmaceutics 13, no. 8 (July 27, 2021): 1151. http://dx.doi.org/10.3390/pharmaceutics13081151.
Повний текст джерелаАнотація:
The encapsulation of therapeutic agents into nano-based drug delivery system for cancer treatment has received considerable attention in recent years. Advancements in nanotechnology provide an opportunity for efficient delivery of anticancer drugs. The unique properties of nanoparticles not only allow cancer-specific drug delivery by inherent passive targeting phenomena and adopting active targeting strategies, but also improve the pharmacokinetics and bioavailability of the loaded drugs, leading to enhanced therapeutic efficacy and safety compared to conventional treatment modalities. Small molecule drugs are the most widely used anticancer agents at present, while biological macromolecules, such as therapeutic antibodies, peptides and genes, have gained increasing attention. Therefore, this review focuses on the recent achievements of novel nano-encapsulation in targeted drug delivery. A comprehensive introduction of intelligent delivery strategies based on various nanocarriers to encapsulate small molecule chemotherapeutic drugs and biological macromolecule drugs in cancer treatment will also be highlighted.
31
Ostroumova, O. D., M. S. Chernyaeva, A. I. Kochetkov, D. I. Bakhteeva, S. N. Ivanov, and D. A. Sychev. "Atrial Fibrillation Associated with Anticancer Drugs." Safety and Risk of Pharmacotherapy 8, no. 4 (December 17, 2020): 178–90. http://dx.doi.org/10.30895/2312-7821-2020-8-4-178-190.
Повний текст джерелаАнотація:
Atrial fibrillation is a serious adverse reaction associated with the use of anticancer drugs. The aim of the study was to analyse scientific literature on the prevalence, pathophysiological mechanisms, and risk factors of anticancer drug-induced atrial fibrillation, ways of its prevention and treatment. The results of the study showed that the incidence of drug-induced atrial fibrillation varies depending on a specific anticancer drug and ranges from 1 to 86%. It is associated with the use of herbal anticancer agents, alkylating agents, protein kinase inhibitors, monoclonal antibodies, immunosuppressants, antitumor antibiotics, antimetabolites, hormonal anticancer agents, hormone antagonists, etc. Most often, atrial fibrillation develops following the use of such drugs as gemcitabine (in combination with vinorelbine), cisplatin, melphalan, ibrutinib, cetuximab, trastuzumab, alemtuzumab, and doxorubicin. It was demonstrated that the pathophysiological mechanisms underlying the development of atrial fibrillation induced by anticancer drugs include electrophysiological abnormalities, myocardial injury, inflammation, immune response, apoptosis, and oxidative stress. Risk factors for the development of anticancer drug-induced atrial fibrillation are not clearly defined yet and continue to be the subject of research. Prevention of drug-induced atrial fibrillation in cancer patients requires a multidisciplinary approach involving participation of an oncohematologist and a cardiologist. The doctors in charge should also be vigilant regarding potential development of this adverse reaction.
32
Yu, Guo, Dan-Na Wu, Yichao Yu, Guo-Fu Li, and Hong-Hao Zhou. "Impact of dosage timing on the bioavailability of oral anticancer medications: Is pre-prandial dosing equivalent to post-prandial dosing." Journal of Oncology Pharmacy Practice 25, no. 2 (January 17, 2018): 404–8. http://dx.doi.org/10.1177/1078155217752535.
Повний текст джерелаАнотація:
Many oral anticancer agents are recommended to be given either at least 1 h before or 2 h after a meal, according to the prescribing information. However, the effect of dosage timing of an oral anticancer agent with reference to food intake on anticancer treatment remains unclear. As shown by the literature survey and labeling analysis for oral anticancer drugs approved by the US Food and Drug Administration from 2010 to 2016, labeling information regarding dosage timing for several anticancer drugs appeared not be optimum, leading to suboptimal bioavailability and plasma drug concentrations. This supports a call to regularly recalibrate the labeling information for dosage timing of oral anticancer medications to minimize the risks of compromised efficacy or unintended toxicities.
33
Torić, Jelena, Ana Karković Marković, Cvijeta Jakobušić Brala, and Monika Barbarić. "Anticancer effects of olive oil polyphenols and their combinations with anticancer drugs." Acta Pharmaceutica 69, no. 4 (December 1, 2019): 461–82. http://dx.doi.org/10.2478/acph-2019-0052.
Повний текст джерелаАнотація:
Abstract Cancer presents one of the leading causes of death in the world. Current treatment includes the administration of one or more anticancer drugs, commonly known as chemotherapy. The biggest issue concerning the chemotherapeutics is their toxicity on normal cells and persisting side effects. One approach to the issue is chemoprevention and the other one is the discovery of more effective drugs or drug combinations, including combinations with polyphenols. Olive oil polyphenols (OOPs), especially hydroxytyrosol (HTyr), tyrosol (Tyr) and their derivatives oleuropein (Ole), oleacein and oleocanthal (Oc) express anticancer activity on different cancer models. Recent studies report that phenolic extract of virgin olive oil may be more effective than the individual phenolic compounds. Also, there is a growing body of evidence about the combined treatment of OOPs with various anticancer drugs, such as cisplatin, tamoxifen, doxorubicin and others. These novel approaches may present an advanced strategy in the prevention and treatment of cancer.
34
Rahmania, Fitriani Jati, Yi-Shou Huang, Yitayal Admassu Workie, Toyoko Imae, Anna Kondo, Yukiko Miki, Ritsuko Imai, et al. "Preparation of Functional Nanoparticles-Loaded Magnetic Carbon Nanohorn Nanocomposites towards Composite Treatment." Nanomaterials 13, no. 5 (February 23, 2023): 839. http://dx.doi.org/10.3390/nano13050839.
Повний текст джерелаАнотація:
Combination therapy for cancer is expected for the synergetic effect of different treatments, and the development of promising carrier materials is demanded for new therapeutics. In this study, nanocomposites including functional nanoparticles (NPs) such as samarium oxide NP for radiotherapy and gadolinium oxide NP as a magnetic resonance imaging agent were synthesized and chemically combined with iron oxide NP-embedded or carbon dot-coating iron oxide NP-embedded carbon nanohorn carriers, where iron oxide NP is a hyperthermia reagent and carbon dot exerts effects on photodynamic/photothermal treatments. These nanocomposites exerted potential for delivery of anticancer drugs (doxorubicin, gemcitabine, and camptothecin) even after being coated with poly(ethylene glycol). The co-delivery of these anticancer drugs played better drug-release efficacy than the independent drug delivery, and the thermal and photothermal procedures enlarged the drug release. Thus, the prepared nanocomposites can be expected as materials to develop advanced medication for combination treatment.
35
Szumilak, Marta, Anna Wiktorowska-Owczarek, and Andrzej Stanczak. "Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?" Molecules 26, no. 9 (April 29, 2021): 2601. http://dx.doi.org/10.3390/molecules26092601.
Повний текст джерелаАнотація:
Despite enormous progress in the treatment of many malignancies, the development of cancer resistance is still an important reason for cancer chemotherapy failure. Increasing knowledge of cancers’ molecular complexity and mechanisms of their resistance to anticancer drugs, as well as extensive clinical experience, indicate that an effective fight against cancer requires a multidimensional approach. Multi-target chemotherapy may be achieved using drugs combination, co-delivery of medicines, or designing hybrid drugs. Hybrid drugs simultaneously targeting many points of signaling networks and various structures within a cancer cell have been extensively explored in recent years. The single hybrid agent can modulate multiple targets involved in cancer cell proliferation, possesses a simpler pharmacokinetic profile to reduce the possibility of drug interactions occurrence, and facilitates the process of drug development. Moreover, a single medication is expected to enhance patient compliance due to a less complicated treatment regimen, as well as a diminished number of adverse reactions and toxicity in comparison to a combination of drugs. As a consequence, many efforts have been made to design hybrid molecules of different chemical structures and functions as a means to circumvent drug resistance. The enormous number of studies in this field encouraged us to review the available literature and present selected research results highlighting the possible role of hybrid drugs in overcoming cancer drug resistance.
36
Hao, Jessica, Ivana Stavljenić Milašin, Zeynep Batu Eken, Marinka Mravak-Stipetic, Krešimir Pavelić, and Fusun Ozer. "Effects of Zeolite as a Drug Delivery System on Cancer Therapy: A Systematic Review." Molecules 26, no. 20 (October 14, 2021): 6196. http://dx.doi.org/10.3390/molecules26206196.
Повний текст джерелаАнотація:
Zeolites and zeolitic imidazolate frameworks (ZIFs) are widely studied as drug carrying nanoplatforms to enhance the specificity and efficacy of traditional anticancer drugs. At present, there is no other systematic review that assesses the potency of zeolites/ZIFs as anticancer drug carriers. Due to the porous nature and inherent pH-sensitive properties of zeolites/ZIFs, the compounds can entrap and selectively release anticancer drugs into the acidic tumor microenvironment. Therefore, it is valuable to provide a comprehensive overview of available evidence on the topic to identify the benefits of the compound as well as potential gaps in knowledge. The purpose of this study was to evaluate the potential therapeutic applications of zeolites/ZIFs as drug delivery systems delivering doxorubicin (DOX), 5-fluorouracil (5-FU), curcumin, cisplatin, and miR-34a. Following PRISMA guidelines, an exhaustive search of PubMed, Scopus, Embase, and Web of Science was conducted. No language or time limitations were used up to 25th August 2021. Only full text articles were selected that pertained to the usage of zeolites/ZIFs in delivering anticancer drugs. Initially, 1279 studies were identified, of which 572 duplicate records were excluded. After screening for the title, abstract, and full texts, 53 articles remained and were included in the qualitative synthesis. An Inter-Rater Reliability (IRR) test, which included a percent user agreement and reliability percent, was conducted for the 53 articles. The included studies suggest that anticancer drug-incorporated zeolites/ZIFs can be used as alternative treatment options to enhance the efficacy of cancer treatment by mitigating the drawbacks of drugs under conventional treatment.
37
Taghipour-Sabzevar, Vahid, Tahere Sharifi, and Mehrdad Moosazadeh Moghaddam. "Polymeric nanoparticles as carrier for targeted and controlled delivery of anticancer agents." Therapeutic Delivery 10, no. 8 (August 2019): 527–50. http://dx.doi.org/10.4155/tde-2019-0044.
Повний текст джерелаАнотація:
In recent decades, many novel methods by using nanoparticles (NPs) have been investigated for diagnosis, drug delivery and treatment of cancer. Accordingly, the potential of NPs as carriers is very significant for the delivery of anticancer drugs, because cancer treatment with NPs has led to the improvement of some of the drug delivery limitations such as low blood circulation time and bioavailability, lack of water solubility, drug adverse effect. In addition, the NPs protect drugs against enzymatic degradation and can lead to the targeted and/or controlled release of the drug. The present review focuses on the potential of NPs that can help the targeted and/or controlled delivery of anticancer agents for cancer therapy.
38
Ostroumova, Olga D., Aleksey I. Kochetkov, and Valeria A. De. "Cancer treatment and drug-induced QT interval prolongation: A review." Consilium Medicum 24, no. 6 (August 15, 2022): 391–98. http://dx.doi.org/10.26442/20751753.2022.6.201542.
Повний текст джерелаАнотація:
Anticancer drugs can cause drug-induced prolongation of the QT interval. Prolongation of the QT interval is a known risk factor and an independent predictor of the development of life-threatening ventricular arrhythmias (polymorphic ventricular tachycardia, also called Torsades de Pointes), and sudden cardiac death in patients with and without structural heart disease. Healthcare practitioners should constantly evaluate the benefit/risk ratio prior to initiating treatment as well as continuing the chosen one. Some patients need particular attention, especially those who have risk factors such as comorbidities, taking drugs associated with QT interval prolongation, dehydration and electrolyte imbalance, etc. Despite apparent increase in the awareness among the patients and medical professionals, many scientists suggest that there is a lack of awareness about the true prevalence of these adverse events, which are at least 10 times greater than reported cases. This article discusses anticancer drugs that have an association with QT interval prolongation, and also possible strategies in the treatment of the patients with drug-induced QT interval prolongation.
39
Xiao, Yuchen, Jianping Yong, Yang Yang, and Canzhong Lu. "The Ethyl Acetate Extraction Obtained from Podocarpus Nagikernel Meal with Anticancer Activity." Biomedical and Pharmacology Journal 14, no. 1 (March 30, 2021): 363–66. http://dx.doi.org/10.13005/bpj/2134.
Повний текст джерелаАнотація:
Cancer is a major public health problem worldwide, and it is one of the top three major diseases in terms of mortality. Some small molecular synthesized drugs have been used clinically. However, much side-effects were also appeared during treatment of the cancer patients with the synthesized anticancer drugs in clinical. Some Chinese Traditional Plant Medicines have ever been used for treatment of cancer with the low side-effects. Thus, it is essential to find anticancer drugs or drug candidates from Chinese Traditional Plant Medicines. Podocarpus nagicontains different kinds of biological components together with a wide spectrum of biological activities, and it has ever been used in the folk of Yao Nationality for treatment different diseases. It is essential to study this folk plant medicine to discover new drugs or drug candidates. In this work, we obtained different polar extractions and evaluated their in vitro anticancer activity.
40
Kumar, Sahil, Bandna Sharma, Kiran Thakur, Tilak R. Bhardwaj, Deo N. Prasad, and Rajesh K. Singh. "Recent Advances in the Development of Polymeric Nanocarrier Formulations for the Treatment of Colon Cancer." Drug Delivery Letters 9, no. 1 (February 6, 2019): 2–14. http://dx.doi.org/10.2174/2210303108666181109120710.
Повний текст джерелаАнотація:
Background: Many efforts have been explored in the last decade to treat colon cancer but nanoparticulate drug delivery systems are making a vital contribution in the improvement of drug delivery to colon cancer cells. Objective: In this review, we attempt to highlight recent advancements in the development of novel drug delivery systems of nanoparticles for the targeted drug delivery to colon. Polymers like Epithelial Cell Adhesion Molecule (EpCAM) aptamer chitosan, Hyaluronic Acid (HA), Chitosan (CS)– Carboxymethyl Starch (CMS), silsesquioxane capped mesoporous silica, Near IR (NIR) fluorescent Human Serum Albumin (HAS), poly(ethylene glycol)-conjugated hyaluronic acid etc. have been discussed by employing various anticancer drugs like doxorubicin, oxaliplatin, paclitaxel, 5-fluorouracil etc. Conclusion: These novel drug delivery systems have been determined to be more efficacious in terms of stability, sustained and targeted drug delivery, therapeutic efficacy, improved bioavailability and enhanced anticancer activity.
41
Qi, Jiating, and Zhuqing Ouyang. "Targeting CDK4/6 for Anticancer Therapy." Biomedicines 10, no. 3 (March 16, 2022): 685. http://dx.doi.org/10.3390/biomedicines10030685.
Повний текст джерелаАнотація:
Cyclin-dependent kinase 4/6 (CDK4/6) are key regulators of the cell cycle and are deemed as critical therapeutic targets of multiple cancers. Various approaches have been applied to silence CDK4/6 at different levels, i.e., CRISPR to knock out at the DNA level, siRNA to inhibit translation, and drugs that target the protein of interest. Here we summarize the current status in this field, highlighting the mechanisms of small molecular inhibitors treatment and drug resistance. We describe approaches to combat drug resistance, including combination therapy and PROTACs drugs that degrade the kinases. Finally, critical issues and perspectives in the field are outlined.
42
Nikolova, Maria P., Enamala Manoj Kumar, and Murthy S. Chavali. "Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment." Pharmaceutics 14, no. 10 (October 15, 2022): 2195. http://dx.doi.org/10.3390/pharmaceutics14102195.
Повний текст джерелаАнотація:
Liposomes are well-known nanoparticles with a non-toxic nature and the ability to incorporate both hydrophilic and hydrophobic drugs simultaneously. As modern drug delivery formulations are produced by emerging technologies, numerous advantages of liposomal drug delivery systems over conventional liposomes or free drug treatment of cancer have been reported. Recently, liposome nanocarriers have exhibited high drug loading capacity, drug protection, improved bioavailability, enhanced intercellular delivery, and better therapeutic effect because of resounding success in targeting delivery. The site targeting of smart responsive liposomes, achieved through changes in their physicochemical and morphological properties, allows for the controlled release of active compounds under certain endogenous or exogenous stimuli. In that way, the multifunctional and stimuli-responsive nanocarriers for the drug delivery of cancer therapeutics enhance the efficacy of treatment prevention and fighting over metastases, while limiting the systemic side effects on healthy tissues and organs. Since liposomes constitute promising nanocarriers for site-targeted and controlled anticancer drug release, this review focuses on the recent progress of smart liposome achievements for anticancer drug delivery applications.
43
Alven, Sibusiso, and Blessing Atim Aderibigbe. "Efficacy of Polymer-Based Nanocarriers for Co-Delivery of Curcumin and Selected Anticancer Drugs." Nanomaterials 10, no. 8 (August 8, 2020): 1556. http://dx.doi.org/10.3390/nano10081556.
Повний текст джерелаАнотація:
Cancer remains a heavy health burden resulting in a high rate of mortality around the world. The presently used anticancer drugs suffer from several shortcomings, such as drug toxicity, poor biodegradability and bioavailability, and poor water solubility and drug resistance. Cancer is treated effectively by combination therapy whereby two or more anticancer drugs are employed. Most of the combination chemotherapies result in a synergistic effect and overcome drug resistance. Furthermore, the design of polymer-based nanocarriers for combination therapy has been reported by several researchers to result in promising therapeutic outcomes in cancer treatment. Curcumin exhibits good anticancer activity but its poor bioavailability has resulted in its incorporation into several polymer-based nanocarriers resulting in good biological outcomes. Furthermore, the incorporation of curcumin together with other anticancer drugs have been reported to result in excellent therapeutic outcomes in vivo and in vitro. Due to the potential of polymer-based nanocarriers, this review article will be focused on the design of polymer-based nanocarriers loaded with curcumin together with other anticancer drugs.
44
Krasnopolsky, Yu, D. Pylypenko, and G. Grigoryeva. "NANOMEDICINE IN ANTICANCER THERAPY." Bulletin of the National Technical University "KhPI". Series: Chemistry, Chemical Technology and Ecology 1, no. 7 (December 30, 2022): 3–13. http://dx.doi.org/10.20998/2079-0821.2022.01.
Повний текст джерелаАнотація:
The use of liposomal nanoparticles as a drug delivery system today is a promising area of modern nanopharmacology, in particular in the development of antitumor drugs. Liposomal forms of antitumor active pharmaceutical ingredients are characterized by reduced toxicity, stability, and increased antitumor activity of nanoparticle-encapsulated antitumor agent, prolonged action of the drug. Commercially available liposomal anticancer drugs are passively targeted drugs that accumulate in cells by passive diffusion in tumor cells due to the EPR effect of the vascular system. This review presents data from the study of antitumor activity of liposomal drugs conducted by Ukrainian scientists in recent decades. Today, the antitumor activity of liposomal forms of therapeutic agents of various natures has been proven, among them are anthracycline antibiotics, platinum drugs, semisynthetic alkaloid derivatives, natural polyphenolic antioxidants, etc. Thus, the encapsulation of doxorubicin hydrochloride in liposomes has reduced its cardiotoxicity and other side effects, provided an opportunity to treat doxorubicin-resistant tumors. Liposomal forms of complex platinum compounds, in particular cisplatin, have been shown to be more effective than free forms of cytostatics in the treatment of cisplatin-resistant ovarian cancer. The use of polyphenolic antioxidants, quercetin and curcumin, in complex therapy can not only enhance the antitumor effect, but also have a protective effect on healthy tissues and organs.
45
Wang, Jianzheng, Jinxi Huang, Hui Wang, Wei Yang, Qiwen Bai, Zhentao Yao, Qingli Li, et al. "Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model." Journal of Oncology 2022 (January 27, 2022): 1–11. http://dx.doi.org/10.1155/2022/1987705.
Повний текст джерелаАнотація:
Background. The morbidity and mortality of gastric cancer are high in China. There are challenges to develop precise and individualized drug regimens for patients with gastric cancer after a standard treatment. Choosing the most appropriate anticancer drug after a patient developing drug resistance is very important to improve the patient’s prognosis. MiniPDX has been widely used as a new and reliable preclinical research model to predict the sensitivity of anticancer drugs. Methods. The OncoVee® MiniPDX system developed by Shanghai LIDE Biotech Co., Ltd. was used to establish the MiniPDX models using specimens of patients with gastric cancer. The cancer tissues were biopsied under endoscopy, and then, the tumor cell suspension was prepared for a drug sensitivity test by subcutaneously implanting into Balb/c-nude mice. The selected optimal regimen obtained from the MiniPDX assay was used to treat patients with drug-resistant gastric cancer. Results. We successfully established an individualized and sensitive drug screening system for four patients from January 2021 to July 2021. MiniPDX models identified potentially effective drugs for these four patients, with partial remission in two of the patients after treatment and disease progression in the remaining of two patients. Severe side effects from chemotherapy or targeted therapy were not observed in all patients. Conclusion. Establishing a personalized drug screening system for patients with drug-resistant gastric cancer can guide the selection of clinical drugs, improve the clinical benefit of patients, and avoid ineffective treatments. It can be an effective supplement for treatment options.
46
Gori, Stefania, Massimo Di Maio, Carmine Pinto, Oscar Alabiso, Editta Baldini, Enrico Barbato, Giordano Domenico Beretta, et al. "Impact of use of Oral Anticancer Drugs on Activity of Italian Oncology Practices: Results of a Survey Conducted by the Italian Society of Medical Oncology (AIOM)." Tumori Journal 99, no. 1 (January 2013): 35–38. http://dx.doi.org/10.1177/030089161309900106.
Повний текст джерелаАнотація:
Aims and background In recent years, the number of oral anticancer drugs used in clinical practice has rapidly increased. The Italian Society of Medical Oncology (AIOM) conducted a survey to describe the impact of the use of oral anticancer drugs on the daily activity of Italian oncology practices. Methods and study design A survey questionnaire was distributed to the coordinators of the regional sections of AIOM. A 6-month period was considered, from January 1, 2010 to June 30, 2010. The survey addressed (1) quantitative aspects of the use of oral anticancer drugs; (2) practical aspects in the management of patients treated with these drugs; (3) issues related to treatment costs and reimbursement procedures. Results Thirty-six questionnaires were received from institutions distributed throughout the Italian territory. Oral anticancer drugs (both chemotherapy and molecularly targeted agents) accounted for a significant proportion (17%) of prescribed treatments. Among the responding institutions, there were different dispensation procedures of oral drugs to patients: drugs were dispensed by the pharmacist (57%) or directly by the medical oncologist (23%) or nurse (20%). The medical oncologist played a major role in the communication with patients (73% alone and a further 24% in cooperation with other professional figures) and was the point of reference in the event of side effects in 97% of cases. In most cases, the reimbursement of drug costs was separated (“File F” procedure) from the flat fare received by the hospital for outpatient visits or day-hospital access. Conclusions Optimal organization of oral anticancer treatment warrants the cooperation and integration of multiple professional figures. At least three figures are involved in patient management in the hospital: the medical oncologist, the nurse, and the hospital pharmacist. Oral anticancer treatments are associated with specific reimbursement issues: in the majority of cases, the cost of the drug is reimbursed separately from the cost of patient access.
47
Gyanani, Vijay, Jeffrey C. Haley, and Roshan Goswami. "Challenges of Current Anticancer Treatment Approaches with Focus on Liposomal Drug Delivery Systems." Pharmaceuticals 14, no. 9 (August 24, 2021): 835. http://dx.doi.org/10.3390/ph14090835.
Повний текст джерелаАнотація:
According to a 2020 World Health Organization report (Globocan 2020), cancer was a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The aim of anticancer therapy is to specifically inhibit the growth of cancer cells while sparing normal dividing cells. Conventional chemotherapy, radiotherapy and surgical treatments have often been plagued by the frequency and severity of side effects as well as severe patient discomfort. Cancer targeting by drug delivery systems, owing to their selective targeting, efficacy, biocompatibility and high drug payload, provides an attractive alternative treatment; however, there are technical, therapeutic, manufacturing and clinical barriers that limit their use. This article provides a brief review of the challenges of conventional anticancer therapies and anticancer drug targeting with a special focus on liposomal drug delivery systems.
48
Bepari, Asmatanzeem, Nayana Sakre, Ishrat Rahman, Shaik Kalimulla Niazi, and Asmabi M. Dervesh. "The Assessment of Drug Utilization Study of Anticancer Drugs Using WHO Prescribing Indicators in a Government Tertiary Care Hospital of the Hyderabad - Karnataka Region of India." Open Access Macedonian Journal of Medical Sciences 7, no. 7 (April 13, 2019): 1203–8. http://dx.doi.org/10.3889/oamjms.2019.249.
Повний текст джерелаАнотація:
BACKGROUND: Cancer is a major burden and threat to global society. A wide range of chemotherapeutic agents is extensively used to treat cancer at different stages. Inappropriate drug use may also lead to the raised cost of medical care, adverse drug effects, and patient mortality. Hence, in recent years, drug utilisation studies have become a potential tool to be used in the evaluation of different health care systems including cancer.
AIMS: The objectives of the study were to identify the various types of cancer, the commonly prescribed drugs, rational use of anticancer drugs, and analyse the prescribing indicators in a tertiary care government hospital of India.
MATERIAL AND METHODS: Newly diagnosed cancer and/or known case of carcinoma of either sex which required treatment/on treatment with chemotherapy aged > 18 yrs admitted in Radiotherapy Department from April 2016 to September 2016 were included in the study and analysed for prescribing indicators.
RESULTS: The head & neck cancers were the prevalent cancers observed with more preponderance among males. Most of the patients were prescribed with a single anticancer drug. Cisplatin was the most commonly used cytotoxic drug followed by carboplatin, and antimetabolites. The most commonly used adjuvant drugs in our study were anti-emetics and anti-peptic ulcer drugs. Over 82% of anticancer agents were taken from the essential drug list and were prescribed in generic names, indicating rational use.
CONCLUSION: Over 82% of anticancer agents were taken from the essential drug list and were prescribed in generic names, indicating rational use.
49
Jiang, Bing-Hua, and Ling-Zhi Liu. "Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment." Drug Resistance Updates 11, no. 3 (June 2008): 63–76. http://dx.doi.org/10.1016/j.drup.2008.03.001.
Повний текст джерела
50
Rogala, Britny G., Margaret M. Charpentier, Michelle K. Nguyen, Kaitlin M. Landolf, Lamya Hamad, and Kelly M. Gaertner. "Oral Anticancer Therapy: Management of Drug Interactions." Journal of Oncology Practice 15, no. 2 (February 2019): 81–90. http://dx.doi.org/10.1200/jop.18.00483.
Повний текст джерелаАнотація:
Oral anticancer therapy is increasingly integrated into the care of patients with cancer. Recognition and management of drug-drug interactions (DDIs) is critical to providing efficacious and safe anticancer treatment. DDIs with QTc-prolonging agents, anticoagulants, enzyme inducers and inhibitors, antidepressants, and acid suppressants are commonly encountered with anticancer therapies. Here, we review frequently observed DDIs and outline literature-supported suggestions for their management.